December 21, 2020 02:00 ET | Source: Allecra Therapeutics GmbH; Shanghai Haini Pharmaceutical Co., Ltd. Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with… Read More
Former CEO and Antios co-founder, Abel De La Rosa, Ph.D., appointed Chairman of the Board of Directors Mayes to lead continued development of ATI-2173 as a potential backbone of a curative regimen for Hepatitis B (“HBV”) ATLANTA, Dec. 01, 2020 (GLOBE NEWSWIRE) — Antios Therapeutics, Inc. (“Antios”) today… Read More
PHOENIX, November 6, 2020 – OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, today announced the appointment of Charles (Chuck) M. Baum, M.D., Ph.D., as chairperson of the company’s board of directors. Dr. Baum is currently president and chief executive officer of Mirati Therapeutics, which develops novel therapeutics that target the genetic… Read More
Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animalsand protects nonhuman primates from SARS-CoV-2 challenge Strong immune response and protection observed with adjuvant systems from GSK and Dynavax led to inclusion of both adjuvants separately into Clover’s ongoing Phase 1 clinical… Read More
BEDFORD, Mass., Sept. 14, 2020 /PRNewswire/ — Rejoni announced today that it has closed a $15 million Series A financing. The round was led by Ascension Ventures, with additional participation from Delos Capital and Sparta Group. Rejoni is using its biomaterials expertise to realize medical devices that improve the outcomes of minimally… Read More
CEPI to invest an additional $66m upfront in Clover’s S-Trimer protein vaccine candidate. Funding will support clinical development in parallel with scale-up of manufacturing capacity to potentially produce hundreds of millions of doses per year. July 08, 2020 04:00 AM Eastern Daylight Time OSLO, Norway–(BUSINESS WIRE)–CEPI, the Coalition… Read More
Clover Biopharmaceuticals initiates phase 1 study using GSK pandemic adjuvant in combination with COVID-19 vaccine candidate SCB-2019 GSK’s scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover today announced the initiation of a Phase 1 clinical study evaluating the company’s COVID-19… Read More
June 07, 2020 09:00 PM Eastern Daylight Time BEIJING–(BUSINESS WIRE)–Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced the completion of a US$ 24 million Series B-2 financing from GL Ventures. This financing round brings Clover’s total capital raised since… Read More
February 25, 2020 07:00 ET | Source: Allecra Therapeutics GmbH EXBLIFEP demonstrated superiority in the primary endpoint of clinical cure and microbiological eradication at test-of-cure over piperacillin-tazobactam EXBLIFEP safety profile was comparable to piperacillin-tazobactam SAINT-LOUIS, France and WEIL AM RHEIN, Germany, Feb. 25, 2020 (GLOBE NEWSWIRE) — Allecra Therapeutics today… Read More
CHENGDU, China, London, UK – 24 February 2020 – Clover Biopharmaceuticals, a China based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced today that it has entered into a research collaboration with GSK for its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer). GSK will provide Clover with its pandemic adjuvant… Read More
